At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Netarsudil ophthalmic solution 0.02% +1 moredrug
Likely dose
Netarsudil 0.02% ophthalmic solution once daily in both eyes in the evening for 7 daysAI-extracted
Key inclusion· 4
- ✓Age ≥18 years
- ✓Ocular hypertension or open-angle glaucoma in both eyes
- ✓Unmedicated intraocular pressure >17 mmHg in one or both eyes AND <30 mmHg in both eyes
- ✓Corrected visual acuity ≥20/200 in each eye
Key exclusion· 8
- ✕Glaucoma with pseudoexfoliation or pigment dispersion component
- ✕History of angle closure or narrow angles
- ✕Intraocular pressure ≥30 mmHg
- ✕Ocular medications within 30 days
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-masked, Randomized, Placebo-controlled Study of the Nocturnal and Diurnal IOP-lowering Effect of Netarsudil Ophthalmic Solution 0.02% in Habitual Positions Over a 24-hour Period.
In Brief
A Phase 2 clinical trial evaluating Netarsudil ophthalmic solution 0.02% and Netarsudil Ophthalmic Solution Vehicle for Ocular Hypertension and Open Angle Glaucoma. Completed, enrolled 12 participants across 1 site.
Detailed Summary
To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Open Angle Glaucoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJul 2016
First PostedAug 2016
Primary CompletionSep 2016
TodayJul 2026
First PostedAug 22, 2016
Enrollment StartJul 1, 2016
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.9 years ago
Interventions
Netarsudil ophthalmic solution 0.02%drug
Once daily in both eyes (OU) in the evening (PM) for 7 days
Netarsudil Ophthalmic Solution Vehicleother
Once daily in both eyes (OU) in the evening (PM) for 7 days